Healthcare Providers and Services
Company Overview of Hackensack University Medical Center
Hackensack University Medical Center operates as a nonprofit teaching and research hospital that provides inpatient and outpatient services in New Jersey. The company offers emergency services, such as pediatric emergency, trauma, emergency preparedness, EM residency, family-centered care, mobile acute care hospital, mobile intensive care unit, and observation unit; and hospital services, including bioethics, communications and public relations, health information, information and guest services, medical physics, nutrition and food management, occupational therapy, pastoral care, pathology, inpatient and outpatient pharmacy, physical therapy, radiology, security, social service, speech thera...
30 Prospect Avenue
Hackensack, NJ 07601
Founded in 1888
Key Executives for Hackensack University Medical Center
Chief Executive Officer, President, Member of Board of Governors and Member of Advisory Board
Chief Financial Officer and Executive Vice President
Executive Vice President of Patient Care Division and Chief Nursing Officer
Chairman of Orthopedic Surgery Department
Chairman of Anesthesiology Department and Member of Advisory Board
Compensation as of Fiscal Year 2017.
Hackensack University Medical Center Key Developments
Hackensack University Medical Center Presents at Premier Annual Breakthroughs Conference and Exhibitions 2017, Jun-27-2017 through Jun-30-2017
Jun 25 17
Hackensack University Medical Center Presents at Premier Annual Breakthroughs Conference and Exhibitions 2017, Jun-27-2017 through Jun-30-2017. Venue: Walter E. Washington Convention Center, 801 Mount Vernon Pl NW, Washington, DC 20001, United States. Presentation Date(s): Jun-28-2017. Jun-29-2017.
Hackensack University Medical Center Announces Clinical Trial Suggests Value of Venetoclax Combination Therapy in Patients with B-Cell Non-Hodgkin Lymphoma
Jun 6 16
A new global multi-center study co-authored by John Theurer Cancer Center (JTCC) at Hackensack University Medical Center researchers and presented here on June 6, 2016 at the American Society of Clinical Oncology (ASCO) annual meeting concludes that venetoclax, a selective, potent oral BCL-2 inhibitor with activity in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) in combination with standard therapeutic regimens, was well-tolerated and provides evidence of its potential therapeutic value in this patient population. The open-label, dose-finding trial, "Phase 1b study of Venetoclax Plus R- or G-CHOP in Patients with B-cell Non-Hodgkin Lymphoma," (Abstract No. 7566, Poster no. 122) evaluated a regimen used commonly in the treatment of NHL known as CHOP (Cyclophosphamide, Hydroxydaunomycin, Oncovin, Prednisone) in combination with either rituximab or obinutuzumab, to which venetoclax was added. Previous studies in NHL xenograft models have shown that venetoclax may enhance efficacy of rituximab plus CHOP (R-CHOP), or obinutuzumab plus CHOP (G-CHOP) therapies. This study sought to assess safety and tolerability of venetoclax in combination with R-CHOP or G-CHOP in patients with no more than one previous course of therapy and to determine the maximum tolerable dose (MTD) and define appropriate dose of venetoclax for a subsequent Phase 2 study and assess optimal therapeutic benefit. Primary outcome measures for the study are incidence of dose-limiting toxicities and complete response (CR) as defined by PET/CT scan and bone marrow examination. The expected study completion date is April 2018. As of November 30, 2015, 46 patients were enrolled in four cohorts and divided into two arms – rituximab plus CHOP (Arm A) and obinutuzumab plus CHOP (Arm B). Patients in cohort 1 received venetoclax 200-800 mg on cycle 1, day 4, and then daily for 8 cycles. In cohorts 2-4, patients received venetoclax on cycle 1, days 4-10 and cycles 2-8, days 1-10. CHOP was administered for six 21-day cycles. Rituximab was given on day 1 of cycles 1-8 (Arm A), while obinutuzumab was given on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-8 (Arm B). The most grade common adverse events were nausea (48%), fatigue (41%), and diarrhea (41%), and the most common grade 3-4 adverse events were neutropenia (37%) and febrile neutropenia (26%). Researchers determined that venetoclax combined with R- or G-CHOP was well-tolerated, and concluded that the appropriate dose for a Phase 2 study combining venetoclax with R-CHOP was 800mg on cycle 1, days 4-10 and cycle 2-8, days 1-10. Dose finding for venetoclax plus G-CHOP dose finding is ongoing, according to the investigators, who will present their latest findings during the ASCO meeting.
Hackensack University Medical Center Partners with CNOW to Launch Innovative Telehealth Pilot
Oct 7 15
CNOW announced strategic partnership with Hackensack University Medical Center. CNOW's telehealth solutions will effectively allow HackensackUMC's medical staff to connect with patients receiving psychiatric care through real-time, interactive video visits in the hospital, to the home, or anywhere services need to be delivered at any time.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|